157 related articles for article (PubMed ID: 32300907)
1. Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2.
Mortensen ACL; Morin E; Brown CJ; Lane DP; Nestor M
EJNMMI Res; 2020 Apr; 10(1):38. PubMed ID: 32300907
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.
Mortensen AC; Spiegelberg D; Haylock AK; Lundqvist H; Nestor M
Int J Oncol; 2018 Jun; 52(6):1875-1885. PubMed ID: 29658563
[TBL] [Abstract][Full Text] [Related]
3. Utilizing CD44v6 and V600EBRAF-mutation for in vitro targeted combination therapy of thyroid carcinomas.
Mortensen ACL; Imgenberg-Kreuz J; Spiegelberg D; Botling J; Nestor M
Heliyon; 2023 Dec; 9(12):e22594. PubMed ID: 38076095
[TBL] [Abstract][Full Text] [Related]
4.
Mohajershojai T; Jha P; Boström A; Frejd FY; Yazaki PJ; Nestor M
Front Oncol; 2022; 12():849338. PubMed ID: 35433442
[TBL] [Abstract][Full Text] [Related]
5. p53-Mediated Radiosensitization of
Lundsten S; Berglund H; Jha P; Krona C; Hariri M; Nelander S; Lane DP; Nestor M
Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827693
[TBL] [Abstract][Full Text] [Related]
6. The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells.
Mortensen ACL; Spiegelberg D; Brown CJ; Lane DP; Nestor M
Front Oncol; 2019; 9():923. PubMed ID: 31616635
[TBL] [Abstract][Full Text] [Related]
7. Potential of a Cetuximab-based radioimmunotherapy combined with external irradiation manifests in a 3-D cell assay.
Ingargiola M; Runge R; Heldt JM; Freudenberg R; Steinbach J; Cordes N; Baumann M; Kotzerke J; Brockhoff G; Kunz-Schughart LA
Int J Cancer; 2014 Aug; 135(4):968-80. PubMed ID: 24615356
[TBL] [Abstract][Full Text] [Related]
8. The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors.
Spiegelberg D; Mortensen AC; Lundsten S; Brown CJ; Lane DP; Nestor M
Cancer Res; 2018 Sep; 78(17):5084-5093. PubMed ID: 30026328
[TBL] [Abstract][Full Text] [Related]
9. An evaluation
Tesson M; Vasan R; Hock A; Nixon C; Rae C; Gaze M; Mairs R
Oncotarget; 2018 Jun; 9(49):29082-29096. PubMed ID: 30018737
[TBL] [Abstract][Full Text] [Related]
10. Real-time viability and apoptosis kinetic detection method of 3D multicellular tumor spheroids using the Celigo Image Cytometer.
Kessel S; Cribbes S; Bonasu S; Rice W; Qiu J; Chan LL
Cytometry A; 2017 Sep; 91(9):883-892. PubMed ID: 28618188
[TBL] [Abstract][Full Text] [Related]
11. Calcium Electroporation Reduces Viability and Proliferation Capacity of Four Uveal Melanoma Cell Lines in 2D and 3D Cultures.
Kraemer MM; Tsimpaki T; Berchner-Pfannschmidt U; Bechrakis NE; Seitz B; Fiorentzis M
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740554
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Uveal Melanoma Cell Lines and Primary Tumor Samples in 3D Culture.
Aughton K; Shahidipour H; Djirackor L; Coupland SE; Kalirai H
Transl Vis Sci Technol; 2020 Jun; 9(7):39. PubMed ID: 32832244
[TBL] [Abstract][Full Text] [Related]
13. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
[TBL] [Abstract][Full Text] [Related]
14. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
15. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).
Ballangrud AM; Yang WH; Charlton DE; McDevitt MR; Hamacher KA; Panageas KS; Ma D; Bander NH; Scheinberg DA; Sgouros G
Cancer Res; 2001 Mar; 61(5):2008-14. PubMed ID: 11280760
[TBL] [Abstract][Full Text] [Related]
16. Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model.
Palubeckaitė I; Venneker S; van den Akker BEWM; Briaire-de Bruijn IH; Boveé JVMG
Clin Orthop Relat Res; 2023 Mar; 481(3):608-619. PubMed ID: 36729612
[TBL] [Abstract][Full Text] [Related]
17. The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model.
Spiegelberg D; Mortensen ACL; Palupi KD; Micke P; Wong J; Vojtesek B; Lane DP; Nestor M
Front Oncol; 2020; 10():1717. PubMed ID: 33014851
[TBL] [Abstract][Full Text] [Related]
18. Pentagalloyl Glucose and Cisplatin Combination Treatment Exhibits a Synergistic Anticancer Effect in 2D and 3D Models of Head and Neck Carcinoma.
Kantapan J; Intachai N; Khamto N; Meepowpan P; Sangthong P; Wantanajittikul K; Dechsupa N; Chitapanarux I
Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890129
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional growth as multicellular spheroid activates the proangiogenic phenotype of colorectal carcinoma cells via LFA-1-dependent VEGF: implications on hepatic micrometastasis.
Valcárcel M; Arteta B; Jaureguibeitia A; Lopategi A; Martínez I; Mendoza L; Muruzabal FJ; Salado C; Vidal-Vanaclocha F
J Transl Med; 2008 Oct; 6():57. PubMed ID: 18844982
[TBL] [Abstract][Full Text] [Related]
20. Radionuclide Therapy of HER2-Expressing Xenografts Using [
Liu Y; Xu T; Vorobyeva A; Loftenius A; Bodenko V; Orlova A; Frejd FY; Tolmachev V
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
